Indian Journal of Obstetrics and Gynecology Research

Comparison of ormeloxifen and mifepristone in management of leiomyoma uterus

Full Text PDF Share on Facebook Share on Twitter

Article Type : Research Article

Author Details: Madhulika Singh*,Amrita Chourasia,Shalini Singh,Nidhi Sachan

Volume : 6

Issue : 2

Online ISSN : 2394-2754

Print ISSN : 2394-2746

Article First Page : 202

Article End Page : 207


Aims and Objectives: To compare the effect of mifepristone and ormeloxifen on symptomatology, size and vascularity of fibroid and also to compare the compliance and side effects of both these drugs.
Materials and Methods: This study was conducted in the department of obstetrics and gynecology at Swaroop Rani Nehru hospital, Allahabad and Kamla Nehru memorial hospital, Allahabad over a period of one year between 2016-2017 in 90 fibroid patients who gave consent for the study. Depending on their choice they were randomly divided into 2 groups. Group A included 44 fibroid patients who were given mifepristone and Group B included 46 fibroid patients were given ormeloxifen. Assessment of heavy menstrual bleeding by pictorial blood loss assessment chart, dysmenorrhea and dyspareunia by visual analogue scale, estimation of hemoglobin and repeat imaging to assess size, number, endometrial thickness, Doppler velocimetry of fibroid was done and all variables were compared in relation to pretreatment and post-treatment parameters by using chi square test.
Results: 97.7% patients in group A and 95.6% patients in group B were compliant towards treatment. A significant reduction in HMB (group A-51.16% to 18.6% $ group B-45.45% to 20.45%),mean pbac score(group A-246.6 to 65.2;p<0>
Conclusion: Mifepristone and ormeloxifen were equally effective for symptomatic relief in fibroid patients. Myoma size was significantly reduced by mifepristone only, with notable endometrial hyperplasia whereas ormeloxifen causes significant reduction in endometrial thickness. No major side effects observed with any of them.

Keywords: Mifepristone, Ormeloxifen, Leiomyoma, SERM, PBAC score.

Doi :-